NCT03482102View on ClinicalTrials.gov

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

May 14, 2018

Primary Completion Date

October 31, 2024

Study Completion Date

October 31, 2026

Conditions
Hepatocellular CarcinomaBiliary Tract Cancer
Interventions
DRUG

Tremelimumab

Tremelimumab target the cancerous proteins and stop the cancer cells from suppressing the immune system

DRUG

Durvalumab

Durvalumab target the cancerous proteins and stop the cancer cells from suppressing the immune system

RADIATION

Radiation

Radiation therapy is used to shrink cancer cells.

Trial Locations (2)

02214

RECRUITING

Massachusetts General Hospital, Boston

02215

RECRUITING

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

Massachusetts General Hospital

OTHER